SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 455 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $377,843 | +5.9% | 3,117 | 0.0% | 0.02% | +5.0% |
| Q2 2023 | $356,959 | -16.9% | 3,117 | 0.0% | 0.02% | -4.8% |
| Q1 2023 | $429,616 | +6.4% | 3,117 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $403,901 | +17.1% | 3,117 | 0.0% | 0.02% | -12.5% |
| Q3 2022 | $345,000 | +47.4% | 3,117 | 0.0% | 0.02% | +60.0% |
| Q2 2022 | $234,000 | -4.1% | 3,117 | 0.0% | 0.02% | +36.4% |
| Q1 2022 | $244,000 | -13.2% | 3,117 | 0.0% | 0.01% | +10.0% |
| Q4 2021 | $281,000 | -2.4% | 3,117 | 0.0% | 0.01% | -52.4% |
| Q3 2021 | $288,000 | +19.0% | 3,117 | 0.0% | 0.02% | +31.2% |
| Q2 2021 | $242,000 | +4.3% | 3,117 | 0.0% | 0.02% | 0.0% |
| Q1 2021 | $232,000 | -56.3% | 3,117 | 0.0% | 0.02% | -44.8% |
| Q4 2020 | $531,000 | +21.2% | 3,117 | 0.0% | 0.03% | -45.3% |
| Q3 2020 | $438,000 | -12.4% | 3,117 | 0.0% | 0.05% | -37.6% |
| Q2 2020 | $500,000 | +63.9% | 3,117 | 0.0% | 0.08% | +19.7% |
| Q1 2020 | $305,000 | -24.1% | 3,117 | 0.0% | 0.07% | -9.0% |
| Q4 2019 | $402,000 | +71.1% | 3,117 | 0.0% | 0.08% | +62.5% |
| Q3 2019 | $235,000 | -50.4% | 3,117 | 0.0% | 0.05% | -52.0% |
| Q2 2019 | $474,000 | +27.4% | 3,117 | 0.0% | 0.10% | +6.4% |
| Q1 2019 | $372,000 | -1.6% | 3,117 | -10.0% | 0.09% | -23.6% |
| Q4 2018 | $378,000 | -32.4% | 3,462 | 0.0% | 0.12% | -14.6% |
| Q3 2018 | $559,000 | +22.1% | 3,462 | 0.0% | 0.14% | +9.1% |
| Q2 2018 | $458,000 | -8.2% | 3,462 | -48.6% | 0.13% | +153.8% |
| Q1 2018 | $499,000 | -48.0% | 6,731 | -60.9% | 0.05% | -3.7% |
| Q4 2017 | $959,000 | -62.9% | 17,231 | -69.7% | 0.05% | -43.8% |
| Q3 2017 | $2,583,000 | -30.8% | 56,949 | -48.6% | 0.10% | -4.0% |
| Q2 2017 | $3,735,000 | -43.1% | 110,812 | -50.0% | 0.10% | -51.0% |
| Q1 2017 | $6,562,000 | +12.4% | 221,691 | +4.2% | 0.20% | +15.3% |
| Q4 2016 | $5,836,000 | -80.9% | 212,776 | -57.1% | 0.18% | -84.6% |
| Q3 2016 | $30,486,000 | +288.9% | 496,434 | +20.8% | 1.15% | +112.8% |
| Q2 2016 | $7,839,000 | -10.7% | 411,077 | -8.6% | 0.54% | +0.4% |
| Q1 2016 | $8,775,000 | +83.7% | 449,526 | +263.0% | 0.54% | +100.7% |
| Q4 2015 | $4,778,000 | – | 123,850 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |